205448-29-9

Basic information

• Product Name: 7-Benzyloxy-6-methoxy-1,4-dihydro-4-quinolinone
• Synonyms: 7-Benzyloxy-6-methoxy-1,4-dihydro-4-quinolinone;7-Benzyloxy-6-methoxy-1H-quinolin-4-one;7-(benzyloxy)-6-Methoxyquinolin-4(1H)-one;7-(Benzyloxy)-6-methoxy-4(1H)-quinolinone
• CAS NO: 205448-29-9
• Molecular Formula: C₁₇H₁₅NO₃
• Molecular Weight: 281.31
• Mol File: 205448-29-9.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 460.0±45.0 °C(Predicted)
• Appearance: /
• Density: 1.218
• PKA: 2.71±0.50(Predicted)
• CAS DataBase Reference: 7-Benzyloxy-6-methoxy-1,4-dihydro-4-quinolinone(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Benzyloxy-6-methoxy-1,4-dihydro-4-quinolinone(205448-29-9)
• EPA Substance Registry System: 7-Benzyloxy-6-methoxy-1,4-dihydro-4-quinolinone(205448-29-9)

Safety Data

• Hazardous Substances Data: 205448-29-9(Hazardous Substances Data)

Usage

General Description

7-Benzyloxy-6-methoxy-1,4-dihydro-4-quinolinone is a chemical compound with the molecular formula C20H19NO3. It is a quinolinone derivative that contains a benzyl and a methoxy group attached to its structure. The compound has potential pharmacological properties and has been studied for its potential use in drug development. It may have applications in the field of medicinal chemistry and could potentially be used as a building block in the synthesis of various pharmaceutical compounds. Additionally, its unique structure and properties make it an interesting target for further research in the fields of organic and medicinal chemistry.

Upstream product

• 205448-28-8 5-{[(3-(benzyloxy)-4-methoxyphenyl)amino]methylene}-2,2-dimethyl-1,3-dioxane-4,6- dione 
• 75665-73-5 1-(2-amino-4-(benzyloxy)-5-methoxyphenyl)ethanone 
• 109-94-4 formic acid ethyl ester 
• 107-31-3 Methyl formate 
• 61324-40-1 3-benzyloxy-4-methoxybenzeneamine 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 75665-88-2 1-(4-(benzyloxy)-5-methoxy-2-nitrophenyl)ethanone 
• 1835-11-6 4-benzyloxy-3-methoxyacetophenone 
• 100-39-0 benzyl bromide 

Downstream Products

• 205448-30-2 7-benzyloxy-4-chloro-6-methoxyquinoline hydrochloride 
• 849217-53-4 trifluoromethanesulfonic acid 7-benzyloxy-6-methoxy-quinolin-4-yl ester 
• 914490-22-5 7-benzyloxy-3-bromo-6-methoxy-1H-quinolin-4-one 
• 286371-49-1 7-(benzyloxy)-4-chloro-6-methoxyquinoline 
• 479690-03-4 7-benzyloxy-4-(2-fluoro-4-nitro-phenoxy)-6-methyloxyquinoline 
• 417725-03-2 7-(benzyloxy)-6-methoxy-4-(4-nitrophenoxy)quinoline 
• 1355031-15-0 4-(4-aminophenoxy)-6-methoxyquinolin-7-ol 
• 1394821-14-7 N-(4-((7-hydroxy-6-methoxyquinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1416320-80-3 N'-(3-fluoro-4-{[6-methoxy-7-({1-[(methylamino)-2-oxoethyl]piperidin-4-yl}oxy)quinolin-4-yl]oxy}phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 479690-04-5 4-(7-(benzyloxy)-6-methoxyquinolin-4-yloxy)-3-fluorobenzenamine 
• 849217-50-1 N-[3-fluoro-4-[[7-hydroxy-6-methoxy-quinolin-4-yl]oxy]phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 

Relevant articles and documents

Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate

A series of 1,6-naphthyridinone-based MET kinase inhibitors bearing quinoline moiety in block A were designed and synthesized based on the structures of Cabozantinib and our reported compound IV. Extensive SAR and DMPK studies led to the identification of 20j, a potent and orally bioavailable MET kinase inhibitor with favorable kinase selectivity. More importantly, 20j exhibited statistically significant tumor growth inhibition (Tumor growth inhibition/TGI of 131%, 4/6 partial regression/PR) in the U-87 MG xeograft model, which is superior to that of Cabozantinib (TGI of 97%, 2/6 PR), and significantly better than that of compound IV (TGI of 15%, 0/6 PR) at the same dose (12.5 mg/kg). Combined with favorable in vitro potency, kinase selectivity, pharmacokinetic profile and in vivo efficacy, the promising antitumor drug candidate 20j has subsequently advanced into preclinical research.

CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS

The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.

Preparation method of 7-benzyloxy-6-methoxy-4-hydroxyquinoline

The invention discloses a preparation method of 7-benzyloxy-6-methoxy-4-hydroxyquinoline. The method comprises the following steps: under the action of anhydrous p-methylbenzenesulfonic acid, carrying out condensation reaction on 3-benzyloxy-4-methoxyanil